A previous study showed that termination of TGF-β signaling following the transduction of the dominant-negative form of TGF-β receptor II diminished TGF-β-mediated inhibition of EBV-specific cytotoxic cells (CTLs) and enhanced CTL lysis of tumor cells in lymphoma patients [16], [17]. This evidence concerns the gene TGFB1 and lymphoma.